Ownership Capital B.V. Sells 28,579 Shares of Insulet Corporation (NASDAQ:PODD)

Ownership Capital B.V. lessened its stake in Insulet Corporation (NASDAQ:PODD - Free Report) by 15.8% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 152,263 shares of the medical instruments supplier's stock after selling 28,579 shares during the period. Insulet accounts for 1.8% of Ownership Capital B.V.'s portfolio, making the stock its 21st largest holding. Ownership Capital B.V. owned about 0.22% of Insulet worth $39,986,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently bought and sold shares of PODD. Diversify Wealth Management LLC increased its stake in shares of Insulet by 27.0% in the 1st quarter. Diversify Wealth Management LLC now owns 3,508 shares of the medical instruments supplier's stock valued at $881,000 after buying an additional 746 shares during the period. Xponance Inc. increased its position in Insulet by 2.8% in the first quarter. Xponance Inc. now owns 16,007 shares of the medical instruments supplier's stock worth $4,204,000 after purchasing an additional 441 shares during the period. Genus Capital Management Inc. increased its position in Insulet by 202.4% in the first quarter. Genus Capital Management Inc. now owns 17,008 shares of the medical instruments supplier's stock worth $4,466,000 after purchasing an additional 33,611 shares during the period. Cerity Partners LLC raised its holdings in Insulet by 28.7% during the 1st quarter. Cerity Partners LLC now owns 10,232 shares of the medical instruments supplier's stock worth $2,687,000 after purchasing an additional 2,284 shares during the last quarter. Finally, Sharpepoint LLC lifted its position in Insulet by 2.3% during the 1st quarter. Sharpepoint LLC now owns 8,192 shares of the medical instruments supplier's stock valued at $2,058,000 after purchasing an additional 182 shares during the period.

Analyst Ratings Changes

PODD has been the subject of a number of analyst reports. Truist Financial began coverage on Insulet in a research note on Monday, June 16th. They set a "buy" rating and a $365.00 price objective for the company. Raymond James Financial reaffirmed an "outperform" rating and issued a $360.00 price target (up from $328.00) on shares of Insulet in a research note on Tuesday, May 27th. Sanford C. Bernstein reissued an "outperform" rating on shares of Insulet in a research note on Friday, May 16th. Barclays upped their target price on shares of Insulet from $234.00 to $266.00 and gave the company an "equal weight" rating in a research note on Wednesday, April 30th. Finally, The Goldman Sachs Group assumed coverage on shares of Insulet in a report on Friday, May 30th. They issued a "buy" rating and a $380.00 target price on the stock. Four investment analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. According to data from MarketBeat, Insulet presently has a consensus rating of "Moderate Buy" and an average price target of $321.00.

Insider Buying and Selling

In other news, SVP John W. Kapples sold 5,278 shares of the company's stock in a transaction that occurred on Wednesday, May 14th. The stock was sold at an average price of $318.47, for a total transaction of $1,680,884.66. Following the sale, the senior vice president owned 23,180 shares in the company, valued at $7,382,134.60. This represents a 18.55% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Company insiders own 0.39% of the company's stock.

Insulet Stock Down 2.7%

Shares of PODD traded down $8.08 during mid-day trading on Friday, hitting $289.32. 507,503 shares of the company's stock were exchanged, compared to its average volume of 720,913. The company has a debt-to-equity ratio of 1.21, a current ratio of 4.47 and a quick ratio of 3.63. Insulet Corporation has a 52 week low of $173.00 and a 52 week high of $329.33. The company has a market cap of $20.36 billion, a PE ratio of 52.04, a P/E/G ratio of 2.65 and a beta of 1.35. The company has a 50-day simple moving average of $307.29 and a 200 day simple moving average of $280.03.

Insulet (NASDAQ:PODD - Get Free Report) last released its earnings results on Thursday, May 8th. The medical instruments supplier reported $1.02 earnings per share for the quarter, beating analysts' consensus estimates of $0.81 by $0.21. Insulet had a net margin of 18.29% and a return on equity of 22.25%. The business had revenue of $569.00 million during the quarter, compared to the consensus estimate of $543.20 million. During the same quarter last year, the firm earned $0.73 earnings per share. The firm's revenue for the quarter was up 28.8% compared to the same quarter last year. On average, research analysts forecast that Insulet Corporation will post 3.92 earnings per share for the current fiscal year.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.